门静脉血栓病因及危险因素研究进展*

doi:10.3969/j.issn.1672-5069.2019.06.001

摘要/Abstract

Key words: portal vein thrombosis, Pathogenesis, Risk factors

陈帅, 杨长青. 门静脉血栓病因及危险因素研究进展^*[J]. 实用肝脏病杂志, 2019, 22(6): 761-764.

Chen Shuai, Yang Changqing.. Pathogenesis and risk factors of portal vein thrombosis[J]. Journal of Practical Hepatology, 2019, 22(6): 761-764.

[1] Balford GW,Stewart TG. Case of enlarged spleen complicated with ascites,both depending upon varicose dilatation and thrombosis of the portal vein. Edinb Med J,1869,14(7):589-598.
[2] Okuda K,Ohnishi K,Kimura K,et al.Incidence of portal vein thrombosis in liver cirrhosis. An angiographic study in 708 patients. Gastroenterology,1985,89(2):279-286.
[3] Ogren M,Bergqvist D,Bjorck M,et al.Portal vein thrombosis:Prevalence,patient characteristics and lifetime risk:A population study based on 23796 consecutive autopsies. World J Gastroenterol,2006,12(13):2115-2119.
[4] Amitrano L,Guardascione MA,Brancaccio V,et al.Risk factors and clinical presentation of portal vein thrombosis in patients with liver cirrhosis. J Hepatol,2004,40(5):736-741.
[5] Harding DJ,Perera MT,Chen F,et al.Portal vein thrombosis in cirrhosis:Controversies and latest developments. World J Gastroenterol,2015,21(22):6769-6784.
[6] Violi F,Corazza GR,Caldwell SH,et al.Portal vein thrombosis relevance on liver cirrhosis:Italian Venous Thrombotic Events Registry. Intern Emerg Med,2016,11(8):1059-1066.
[7] Ponziani FR,Zocco MA,Campanale C,et al.Portal vein thrombosis:Insight into physiopathology,diagnosis,and treatment. World J Gastroenterol,2010,16(2):143-155.
[8] 姚戈冰,鲁建国.门静脉血栓的发病机制及诊治.肝胆外科杂志,2009,17(2):151-154.
[9] García-Pagán JC,Busacarini E,Janssen HLA,et al.EASL Clinical Practice Guidelines:Vascular diseases of the liver. J Hepatol,2016,64(1):179-202.
[10] DeLeve LD,Valla DC,Garcia-Tsao G,et al. Vascular disorders of the liver. Hepatology,2009,49(5):1729-1764.
[11] Basit SA,Stone CD,Gish R.Portal vein thrombosis. Clin Liver Dis,2015,19(1):199-221.
[12] Trebicka J,Strassburg CP.Etiology and complications of portal vein thrombosis.Viszeralmedizin,2014,30(6):375-380.
[13] Battistelli S,Coratti F,Gori T.Porto-spleno-mesenteric venous thrombosis. Int Angiol,2011,30(1):1-11.
[14] 熊静平,张跃新.肝硬化合并门静脉血栓的研究现状.临床肝胆病杂志,2016,32(6):1075-1078.
[15] Riva N,Donadini MP,Dentali F,et al.Clinical approach to splanchnic vein thrombosis:Risk factors and treatment. Thromb Res,2012,130(Suppl 1):S1-S3.
[16] Zocco MA,Di Stasio E,De Cristofaro R,et al.Thrombotic risk factors in patients with liver cirrhosis:Correlation with MELD scoring system and portal vein thrombosis development. J Hepatol,2009,51(4):682-689.
[17] 刘明涛,韩国宏,王建宏,等.肝硬化门静脉高压患者门静脉压力与血流动力学的关系.中华肝脏病杂志,2004,12(8):504-505.
[18] Maruyama H,Okugawa H,Takahashi M,et al.De novo portal vein thrombosis in virus-related cirrhosis:Predictive factors and long-term Outcomes. Am J Gastroenterol,2013,108(4):568-574.
[19] Zampino R,Lebano R,Coppola N,et al.The use of nonselective beta blockers is a risk factor for portal vein thrombosis in cirrhotic patients. Saudi J Gastroenterol,2018,24(1):25-29.
[20] Qi X,Chen H,Han G.Effect of antithrombin,protein C and protein S on portal vein thrombosis in liver cirrhosis:a meta-a
nalysis. Am J Med Sci,2013,346(1):38-44.
[21] 卢晓敏,王振宁,杨军. 肝硬化患者血栓前状态分子标志物对门静脉血栓形成的监测意义. 临床肝胆病杂志,2015,31(3):404-406.
[22] 李兰娟. 中国消化道微生态调节剂临床应用共识(2016年版).中国微生态学杂志,2016,28( 6):621-631.
[23] Violi F,Lip GY,Cangemi R.Endotoxemia as a trigger of thrombosis in cirrhosis. Haematologica,2016,101(4):e162-e163.
[24] 王新保,杨镇,李德旭,等. 门静脉高压症病人肝内血管内皮细胞凋亡的研究. 中华肝胆外科杂志,2002,8(1):28-30.
[25] Northup PG,Caldwell SH.Coagulation in liver disease:a guide for the clinician. Clin Gastroenterol Hepatol,2013,11(9):1064-1074.
[26] Caldwell SH,Hoffman M,Lisman T,et al.Coagulation disorders and hemostasis in liver disease:Pathophysiology and critical assessment of current management. Hepatology,2006,44(4):1039-1046.
[27] Chen H,Liu L,Qi X,et al.Imbalance of pro-vs. anti-coagulation factors in Chinese patients with Budd-Chiari syndrome and non-cirrhotic portal vein thrombosis. PLoS One,2015,10(3):e0119909.
[28] 田颖,陈文明,张冬磊,等. 肝硬化患者门静脉血栓形成的多因素分析. 中国医师进修杂志,2012,35(22):21-24.
[29] Abdel-Razik A,Mousa N,Elhelaly R,et al.De-novo portal vein thrombosis in liver cirrhosis:risk factors and correlation with the Model for End-stage Liver Disease scoring system.Eur J Gastroenterol Hepatol,2015,27(5):585-592.
[30] Qi X,Han G,Ye C,et al.Splenectomy causes 10-fold increased risk of portal venous system thrombosis in liver cirrhosis patients. Med Sci Monit,2016,22:2528-2550.
[31] 孙隆慈,罗蒙. 门静脉高压症中门静脉血栓的发生机制及诊治进展. 肝胆胰外科杂志,2011,23(1):84-86.
[32] 匡洁,杨卫平,陈皓,等. 门静脉高压症术后门静脉血栓形成的危险因素分析. 外科理论与实践,2012,17(6):634-638.
[33] Kuroki T,Kitasato A,Tokunaga T,e t al. Predictors of portal and splenic vein thrombosis after laparoscopic splenectomy:a retrospective analysis of a single-center experience. Surg Today,2018,48(8):804-809.
[34] Danno K,Ikeda M,Sekimoto M,et al.Diameter of splenic vein is a risk factor for portal or splenic vein thrombosis after laparoscopic splenectomy.Surgery,2009,145(5):457-464.
[35] 陈炜,吴志勇.肝硬化门静脉高压症术后门静脉血栓形成的机制. 肝胆外科杂志,2015,23(5):321-323.
[36] Wang L,Liu GJ,Chen YX,et al.Combined use of D-dimer and P-selectin for the diagnosis of splenic or portal vein thrombosis following splenectomy. Thromb Res,2010,125(5):e206-e209.
[37] Wei Y,Chen X,Shen H,et al.P-Selectin Level at First and Third Day After Portal Hypertensive Splenectomy for Early Prediction of Portal Vein Thrombosis in Patients With Cirrhosis. Clin Appl Thromb Hemost,2018:1-8.
[38] Sobhonslidsuk A,Reddy KR.Portal vein thrombosis:a concise review. Am J Gastroenterol,2002,97(3):535-541.
[39] Zanetto A,Campello E,Spiezia L,et al.Cancer-Associated Thrombosis in Cirrhotic Patients with Hepatocellular Carcinoma.Cancers,2018,10(11):450.
[40] Falanga A.Mechanisms of Hypercoagulation in Malignancy and during Chemotherapy. Haemostasis,1998,28(Suppl 3):50-60.
[41] Plessier A,Rautou PE,Valla DC.Management of hepatic vascular diseases. J Hepatol,2012,56(Suppl 1):S25-S38.
[42] Kumar A,Sharma P,Arora A.Review article:portal vein obstruction-epidemiology,pathogenesis,natural history,prognosis and treatment. Aliment Pharmacol Ther,2015,41(3):276-292.
[43] Qi X,Ren W,De Stefano V,et al.Associations of Coagulation Factor V Leiden and Prothrombin G20210A Mutations With Budd-Chiari Syndrome and Portal Vein Thrombosis:A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol,2014,12(11):1801-1812,e1807.
[44] Qi X,De Stefano V,Wang J,et al.Prevalence of inherited antithrombin,protein C,and protein S deficiencies in portal vein system thrombosis and Budd-Chiari syndrome:A systematic review and meta-analysis of observational studies. J Gastroenterol Hepatol,2013,28(3):432-442.

门静脉血栓病因及危险因素研究进展^*

Pathogenesis and risk factors of portal vein thrombosis

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	庄莹, 林志辉. 肝硬化并发门静脉血栓临床表现和诊断进展[J]. 实用肝脏病杂志, 2019, 22(6): 765-767.
[2]	鲍应军, 任伟新. 门静脉血栓介入治疗研究进展[J]. 实用肝脏病杂志, 2019, 22(6): 768-769.
[3]	丁利敏, 王飞, 朴莲淑, 张孟, 刘城, 李芊蔚, 徐德魁, 于庆功. 202例肝功能异常患者病因分析[J]. 实用肝脏病杂志, 2019, 22(6): 856-859.
[4]	何志安, 余丽萍, 赖江琼, 黄思付. ARFI评估肝硬化并发食管胃底静脉曲张患者出血和门静脉血栓的价值分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 888-891.
[5]	徐祺林, 郝少欢, 冉博. 肝硬化脾切除术后门静脉系统血栓形成的危险因素分析*[J]. 实用肝脏病杂志, 2019, 22(5): 708-711.
[6]	邱军, 王雪清, 张波, 吕波. 经皮胆道造瘘碎石取石术治疗肝内胆管结石患者疗效分析[J]. 实用肝脏病杂志, 2019, 22(5): 744-747.
[7]	黄志寅, 李静. 肝硬化脾切除术利弊权衡细思量[J]. 实用肝脏病杂志, 2019, 22(4): 459-461.
[8]	张微, 史军梅, 王倩. 新生儿发生高胆红素血症危险因素分析[J]. 实用肝脏病杂志, 2019, 22(4): 534-536.
[9]	李芳, 邹桂舟, 叶珺, 郜玉峰. 失代偿期肝硬化并发败血症患者临床特征及其危险因素分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 557-560.
[10]	刘彦君, 李光明. 肝硬化并发门静脉血栓防治研究进展[J]. 实用肝脏病杂志, 2019, 22(4): 605-608.
[11]	肖科, 潘志华, 涂波, 陈丽. 术前CT/MRI检查指标对肝硬化脾切除术后门静脉血栓形成的预测价值[J]. 实用肝脏病杂志, 2019, 22(3): 417-420.
[12]	刘文博, 张建业, 保积武. ERCP和EST治疗胆总管结石复发危险因素分析[J]. 实用肝脏病杂志, 2019, 22(3): 437-440.
[13]	吴亚平,周冰清,蒋蓓莉. 慢性丙型肝炎患者发生重度肝纤维化相关因素分析^*[J]. 实用肝脏病杂志, 2019, 22(2): 196-199.
[14]	赵晓飞,林栋栋,李宁,臧运金,郭庆良,武聚山. 脾切除联合食管胃底曲张静脉断流术后应用华法林对门静脉血栓的防治作用[J]. 实用肝脏病杂志, 2019, 22(2): 240-243.
[15]	王军艳, 陈建婷, 张婷, 范丽, 杜姗, 蒋承志, 牟花妮. 乙型肝炎肝硬化患者院内获得性感染相关危险因素分析^*[J]. 实用肝脏病杂志, 2019, 22(1): 101-104.